Transgenic Mouse Facility

转基因/基因敲除小鼠核心(TMC)的目标是生产出与体内一样的转基因小鼠 探索基因正常功能的模型，以及基因突变在病因和疾病中的作用 癌症的治疗。可以在实验室基因组中引入的修饰范围 小鼠包括整合在功能获得和细胞标记中有用外源DMA(转基因)，以及 基因功能的精确切除(敲除)或改变(敲入)，可以在组织上特定地控制 而且是暂时的。转基因和敲除/敲除小鼠通常是 在体外启动的研究，并提供了一个更具解剖学和生理学相关性的模型系统 人类疾病。转基因小鼠一直是阐明这种分子的重要工具。 支持多种类型的癌症，并补充了传统的异种皮下移植模型 测试新的抗癌疗法。最近12个月报告期(2005年1月至 2005年12月)来自3个项目的9名癌症中心成员和1名不结盟成员使用 转基因/基因敲除小鼠共享资源。提供同行评审资金的用户数量 占用户总数的66%。核心的年度预算为269,657美元，其中68%来自机构，13%来自用户 费用，以及向CCSG申请的19%(50,000美元)。

The goal of the Transgenic/knock-out Mouse Core (TMC) is to produce genetically modified mice as in vivo models for exploring the normal function of genes, and the role of genetic mutations in the etiology and treatment of cancer. The range of modifications that can be introduced into the genome of the laboratory mouse include integration of exogenous DMA (transgenes) useful in gain-of-function and cell labeling, and the precise excision (knock-out) or alteration (knock-in) of gene function that can be controlled both tissuespecifically and temporally. Transgenic and knock-in/knock-out mice are often the logical extension of studies initiated in vitro, and provide a model system with greater anatomical and physiological relevance to human disease. Genetically modified mice have been essential tools in elucidating the molecular underpinnings of many types of cancer, and supplement the traditional sub-cutaneous xenograft model for testing new anti-cancer therapies. During the most recent 12-month reporting period (January 2005 to December 2005) nine Cancer Center members from 3 programs and one non-aligned member used the transgenic/knock-out mouse shared resource. The number of users with peer-reviewed funding represented 66% of users overall. Annual budget for the core is $269,657, with 68% from the institution, 13% from user fees, and 19% ($50,000) requested from the CCSG.